Compare Corsair Gaming Inc (CRSR) vs 10X Genomics Inc (TXG) Price & Performance

Corsair Gaming (CRSR) trades at $12.96, down 5.47% today, but maintains a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with EPS of $0.23 versus $0.07 expected, and the company raised full-year guidance. Revenue for 2025 was $1.47 billion, though net income was negative $16.16 million, reflecting a net margin of -1.1%. The stock's valuation shows a P/E of 41.39 and P/S of 0.95, with analyst consensus leaning toward Hold but with a $12.40 price target slightly below current levels.

The outlook for CRSR is mixed; strong earnings beats and raised guidance signal operational improvement, but profitability remains a challenge with inconsistent net income. Key risks include competitive pressures in gaming hardware and reliance on consumer spending cycles. Upside potential hinges on sustained margin expansion and successful integration of recent acquisitions like Trak Racer.

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.